Ik–Kyung Jang
경희대학교 의예과 · 의학
이 교수의 연구실은 관상동맥 질환의 병태생리학적 기전을 밝히고자, 특히 혈전 형성과 혈관 내 플라크의 생체내 동역학을 분석하는 데 초점을 맞추고 있습니다. 옴니티카라프트 오르가닉스토리오(Oct)를 활용한 관상동맥 플라크의 정밀 분석과 헤파린 유도 혈소판 감소증(HIT) 등 항응고 치료와 관련된 혈전성 합병증에 대한 기전 연구를 진행하고 있습니다. 특히 혈전 용해제의 효능과 항응고제의 작용 메커니즘을 동물 모델을 통해 평가하는 기초 임상 연구를 중심으로 하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
OCT is a safe and effective modality for characterizing coronary atherosclerotic plaques in vivo. Thin-cap fibroatheroma was more frequently observed in patients with AMI or ACS than SAP. This is the first study to compare detailed in vivo plaque morphology in patients with different clinical presentations.
Acute myocardial infarction is triggered by coronary artery occlusion that may be recanalized by thrombolytic therapy with a success rate of up to 75% only. The resistance of coronary artery occlusion to thrombolysis may either be due to obstruction of the lumen by a nonthrombotic mechanism or by intrinsic resistance of thrombus to dissolution. Coronary arterial thrombi are composed of platelet-rich and erythrocyte-rich material in variable proportions. To evaluate the relative sensitivity of th
H eparin-induced thrombocytopenia (HIT; sometimes known as HIT type II) is a serious, immune systemmediated complication of heparin therapy often resulting in devastating thromboembolic outcomes. Although nomenclature distinctions have been made historically between this condition and the non-immune system-mediated, asymptomatic transient drop in platelet count in some patients receiving heparin (sometimes known as HIT type I), the term "HIT" is now preferably reserved for the immune system-medi
The effect of heparin and of the synthetic competitive thrombin inhibitor (2R,4R)-4-methyl-1-[N2-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfon yl)-L-arginyl]-2-piperidinecarboxylic acid monohydrate (argatroban) on platelet-rich arterial thrombosis was studied in a rabbit model, consisting of a 4-6-mm everted ("inside-out") femoral arterial segment. Intravenous injection of heparin (200 units/kg) failed to prevent occlusion within 60 minutes in all 10 rabbits, whereas intravenous argatroban infu